Search

Your search keyword '"Ehgoetz Martens, Kaylena"' showing total 256 results
Start Over Author "Ehgoetz Martens, Kaylena"
256 results on '"Ehgoetz Martens, Kaylena"'

1. Effect of dopamine on limbic network connectivity at rest in Parkinson’s disease patients with freezing of gait

Author

Quek Dione Y. L., Taylor Natasha, Gilat Moran, Lewis Simon J. G., and Ehgoetz Martens Kaylena A.

Subjects
freezing of gait, anxiety, fmri, resting state, parkinson’s disease, amygdala, striatum, emotion, levodopa, resting-state functional connectivity, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

Freezing of gait (FOG) in Parkinson’s disease (PD) has a poorly understood pathophysiology, which hinders treatment development. Recent work showed a dysfunctional fronto-striato-limbic circuitry at rest in PD freezers compared to non-freezers in the dopamine “OFF” state. While other studies found that dopaminergic replacement therapy alters functional brain organization in PD, the specific effect of dopamine medication on fronto-striato-limbic functional connectivity in freezers remains unclear.

Published
2024
Full Text
View/download PDF

5. Neural correlates of trait anxiety in sensory processing and distractor filtering.

Author

Faerman, Michelle V., Ehgoetz Martens, Kaylena A., Meehan, Sean K., and Staines, W. Richard

Subjects
*VISUAL perception, *YOUNG adults, *SENSORIMOTOR integration, *ANXIETY, *ELECTROENCEPHALOGRAPHY
Abstract

Evidence suggests that trait anxiety relates to cognitive processing and behavior. However, the relationships between trait anxiety and sensory processing, goal‐directed performance and sensorimotor function are unclear, particularly in a multimodal context. This study used electroencephalography to evaluate whether trait anxiety influenced visual and tactile event‐related potentials (ERPs), as well as behavioral distractor cost, in a bimodal sensorimotor task. Twenty‐nine healthy young adults completed the State–Trait Anxiety Inventory. Participants were directed to focus on either tactile or visual stimuli while disregarding the other modality, responding to target stimulus amplitude with a proportional grip. Previous research suggests that somatosensory N70 and visual P2 ERPs serve as markers of attentional relevance, with attention also impacting the visual P3 ERP. It was hypothesized that trait anxiety would modulate the ERPs susceptible to attentional modulation (tactile N70, visual P2 and P3) and not affect behavioral performance. Trait anxiety showed a large, significant interaction with attention for visual P3 latency in response to unimodal visual stimuli, with a positive relationship between P3 latencies and trait anxiety when attending toward the stimulus and negative when attending away. A large, positive main effect of trait anxiety on visual N1 amplitude for bimodal stimuli was also detected. As predicted, trait anxiety related to ERPs but not behavioral distractor cost. These findings suggest that trait anxiety modulates visual but not somatosensory processing correlates based on attention. The absence of overt behavioral performance effects suggests compensatory mechanisms may offset underlying differences in sensory processing. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Author

Miglis, Mitchell G, Adler, Charles H, Antelmi, Elena, Arnaldi, Dario, Baldelli, Luca, Boeve, Bradley F, Cesari, Matteo, Dall'Antonia, Irene, Diederich, Nico J, Doppler, Kathrin, Dušek, Petr, Ferri, Raffaele, Gagnon, Jean-François, Gan-Or, Ziv, Hermann, Wiebke, Högl, Birgit, Hu, Michele T, Iranzo, Alex, Janzen, Annette, Kuzkina, Anastasia, Lee, Jee-Young, Leenders, Klaus L, Lewis, Simon J G, Liguori, Claudio, Liu, Jun, Lo, Christine, Ehgoetz Martens, Kaylena A, Nepozitek, Jiri, Plazzi, Giuseppe, Provini, Federica, Puligheddu, Monica, Rolinski, Michal, Rusz, Jan, Stefani, Ambra, Summers, Rebekah L S, Yoo, Dallah, Zitser, Jennifer, and Oertel, Wolfgang H

Published
2021
Full Text
View/download PDF

7. Higher Order Polynomial Transformer for Fine-Grained Freezing of Gait Detection

Author

Sun, Renfei, Hu, Kun, Ehgoetz Martens, Kaylena A., Hagenbuchner, Markus, Tsoi, Ah Chung, Bennamoun, Mohammed, Lewis, Simon J. G., and Wang, Zhiyong

Abstract

Freezing of Gait (FoG) is a common symptom of Parkinson’s disease (PD), manifesting as a brief, episodic absence, or marked reduction in walking, despite a patient’s intention to move. Clinical assessment of FoG events from manual observations by experts is both time-consuming and highly subjective. Therefore, machine learning-based FoG identification methods would be desirable. In this article, we address this task as a fine-grained human action recognition problem based on vision inputs. A novel deep learning architecture, namely, higher order polynomial transformer (HP-Transformer), is proposed to incorporate pose and appearance feature sequences to formulate fine-grained FoG patterns. In particular, a higher order self-attention mechanism is proposed based on higher order polynomials. To this end, linear, bilinear, and trilinear transformers are formulated in pursuit of discriminative fine-grained representations. These representations are treated as multiple streams and further fused by a cross-order fusion strategy for FoG detection. Comprehensive experiments on a large in-house dataset collected during clinical assessments demonstrate the effectiveness of the proposed method, and an area under the receiver operating characteristic (ROC) curve (AUC) of 0.92 is achieved for detecting FoG.

Published
2024
Full Text
View/download PDF

9. Vision-Based Freezing of Gait Detection with Anatomic Patch Based Representation

Author

Hu, Kun, Wang, Zhiyong, Ehgoetz Martens, Kaylena, Lewis, Simon, Hutchison, David, Editorial Board Member, Kanade, Takeo, Editorial Board Member, Kittler, Josef, Editorial Board Member, Kleinberg, Jon M., Editorial Board Member, Mattern, Friedemann, Editorial Board Member, Mitchell, John C., Editorial Board Member, Naor, Moni, Editorial Board Member, Pandu Rangan, C., Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Terzopoulos, Demetri, Editorial Board Member, Tygar, Doug, Editorial Board Member, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Jawahar, C. V., editor, Li, Hongdong, editor, Mori, Greg, editor, and Schindler, Konrad, editor

Published
2019
Full Text
View/download PDF

21. Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study

Author

Joza, Stephen, Hu, Michele T, Jung, Ki-Young, Kunz, Dieter, Stefani, Ambra, Dušek, Petr, Terzaghi, Michele, Arnaldi, Dario, Videnovic, Aleksandar, Schiess, Mya C, Hermann, Wiebke, Lee, Jee-Young, Ferini-Strambi, Luigi, Lewis, Simon J G, Leclair-Visonneau, Laurène, Oertel, Wolfgang H, Antelmi, Elena, Sixel-Döring, Friederike, Cochen De Cock, Valérie, Liguori, Claudio, Liu, Jun, Provini, Federica, Puligheddu, Monica, Nicoletti, Alessandra, Bassetti, Claudio L A, Bušková, Jitka, Dauvilliers, Yves, Ferri, Raffaele, Montplaisir, Jacques Y, Lawton, Michael, Kim, Han-Joon, Bes, Frederik, Högl, Birgit, Šonka, Karel, Fiamingo, Giuseppe, Pietro, Mattioli, Lavadia, Maria Lorena, Suescun, Jessika, Woo, Kyung Ah, Marelli, Sara, Ehgoetz Martens, Kaylena, Janzen, Annette, Plazzi, Giuseppe, Mollenhauer, Brit, Fernandes, Mariana, Li, Yuanyuan, Cortelli, Pietro, Figorilli, Michela, Cicero, Calogero Edoardo, Schaefer, Carolin, Guiraud, Lily, Lanza, Giuseppe, Gagnon, Jean-François, Sunwoo, Jun-Sang, Ibrahim, Abubaker, Girtler, Nicola, Trenkwalder, Claudia, Baldelli, Luca, Pelletier, Amelie, and Postuma, Ronald B

Subjects
REM sleep behavior disorder, evolution, Parkinson’s disease, Neurology (clinical), prodromal stage, 610 Medicine & health, dementia with Lewy bodies
Abstract

The neurodegenerative synucleinopathies, including Parkinson’s disease and dementia with Lewy bodies, are characterized by a typically lengthy prodromal period of progressive subclinical motor and non-motor manifestations. Among these, idiopathic REM sleep behaviour disorder is a powerful early predictor of eventual phenoconversion, and therefore represents a critical opportunity to intervene with neuroprotective therapy. To inform the design of randomized trials, it is essential to study the natural progression of clinical markers during the prodromal stages of disease in order to establish optimal clinical end points. In this study, we combined prospective follow-up data from 28 centres of the International REM Sleep Behavior Disorder Study Group representing 12 countries. Polysomnogram-confirmed REM sleep behaviour disorder subjects were assessed for prodromal Parkinson’s disease using the Movement Disorder Society criteria and underwent periodic structured sleep, motor, cognitive, autonomic and olfactory testing. We used linear mixed-effect modelling to estimate annual rates of clinical marker progression stratified by disease subtype, including prodromal Parkinson’s disease and prodromal dementia with Lewy bodies. In addition, we calculated sample size requirements to demonstrate slowing of progression under different anticipated treatment effects. Overall, 1160 subjects were followed over an average of 3.3 ± 2.2 years. Among clinical variables assessed continuously, motor variables tended to progress faster and required the lowest sample sizes, ranging from 151 to 560 per group (at 50% drug efficacy and 2-year follow-up). By contrast, cognitive, olfactory and autonomic variables showed modest progression with higher variability, resulting in high sample sizes. The most efficient design was a time-to-event analysis using combined milestones of motor and cognitive decline, estimating 117 per group at 50% drug efficacy and 2-year trial duration. Finally, while phenoconverters showed overall greater progression than non-converters in motor, olfactory, cognitive and certain autonomic markers, the only robust difference in progression between Parkinson’s disease and dementia with Lewy bodies phenoconverters was in cognitive testing. This large multicentre study demonstrates the evolution of motor and non-motor manifestations in prodromal synucleinopathy. These findings provide optimized clinical end points and sample size estimates to inform future neuroprotective trials.

Published
2023

42. A Prodromal Brain‐Clinical Pattern of Cognition in Synucleinopathies

Author

Rahayel, Shady, primary, Postuma, Ronald B., additional, Montplaisir, Jacques, additional, Mišić, Bratislav, additional, Tremblay, Christina, additional, Vo, Andrew, additional, Lewis, Simon, additional, Matar, Elie, additional, Ehgoetz Martens, Kaylena, additional, Blanc, Frédéric, additional, Yao, Chun, additional, Carrier, Julie, additional, Monchi, Oury, additional, Gaubert, Malo, additional, Dagher, Alain, additional, and Gagnon, Jean‐François, additional

Published
2020
Full Text
View/download PDF

50. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study

Author

Postuma, Ronald, Iranzo, Alex, Hu, Michele, Högl, Birgit, Boeve, Bradley, Manni, Raffaele, Oertel, Wolfgang, Arnulf, Isabelle, Ferini-Strambi, Luigi, Puligheddu, Monica, Antelmi, Elena, Cochen De Cock, Valérie, Arnaldi, Dario, Mollenhauer, Brit, Videnovic, Aleksandar, Sonka, Karel, Jung, Ki-Young, Kunz, Dieter, Dauvilliers, Yves, Provini, Federica, Lewis, Simon, Buskova, Jitka, Pavlova, Milena, Heidbreder, Anna, Montplaisir, Jacques, Santamaria, Joan, Barber, Thomas, Stefani, Ambra, St Louis, Erik, Terzaghi, Michele, Janzen, Annette, Leu-Semenescu, Smandra, Plazzi, Guiseppe, Nobili, Flavio, Sixel-Doering, Friederike, Dusek, Petr, Bes, Frederik, Cortelli, Pietro, Ehgoetz Martens, Kaylena, Gagnon, Jean-François, Gaig, Carles, Zucconi, Marco, Trenkwalder, Claudia, Gan-Or, Ziv, Lo, Christine, Rolinski, Michal, Mahlknecht, Philip, Holzknecht, Evi, Boeve, Angel, Teigen, Luke, Toscano, Gianpaolo, Mayer, Geert, Morbelli, Silvia, Dawson, Benjamin, Pelletier, Amélie, St.Louis, Erik, Postuma, R. B., Iranzo, A., Hu, M., Hogl, B., Boeve, B. F., Manni, R., Oertel, W. H., Arnulf, I., Ferini-Strambi, L., Puligheddu, M., Antelmi, E., Cochen De Cock, V., Arnaldi, D., Mollenhauer, B., Videnovic, A., Sonka, K., Jung, K. -Y., Kunz, D., Dauvilliers, Y., Provini, F., Lewis, S. J., Buskova, J., Pavlova, M., Heidbreder, A., Montplaisir, J. Y., Santamaria, J., Barber, T. R., Stefani, A., Louis, S. E. K., Terzaghi, M., Janzen, A., Leu-Semenescu, S., Plazzi, G., Nobili, F., Sixel-Doering, F., Dusek, P., Bes, F., Cortelli, P., Ehgoetz Martens, K., Gagnon, J. -F., Gaig, C., Zucconi, M., Trenkwalder, C., Gan-Or, Z., Lo, C., Rolinski, M., Mahlknecht, P., Holzknecht, E., Boeve, A. R., Teigen, L. N., Toscano, G., Mayer, G., Morbelli, S., Dawson, B., Pelletier, A., Postuma R.B., Iranzo A., Hu M., Hogl B., Boeve B.F., Manni R., Oertel W.H., Arnulf I., Ferini-Strambi L., Puligheddu M., Antelmi E., Cochen De Cock V., Arnaldi D., Mollenhauer B., Videnovic A., Sonka K., Jung K.-Y., Kunz D., Dauvilliers Y., Provini F., Lewis S.J., Buskova J., Pavlova M., Heidbreder A., Montplaisir J.Y., Santamaria J., Barber T.R., Stefani A., Louis S.E.K., Terzaghi M., Janzen A., Leu-Semenescu S., Plazzi G., Nobili F., Sixel-Doering F., Dusek P., Bes F., Cortelli P., Ehgoetz Martens K., Gagnon J.-F., Gaig C., Zucconi M., Trenkwalder C., Gan-Or Z., Lo C., Rolinski M., Mahlknecht P., Holzknecht E., Boeve A.R., Teigen L.N., Toscano G., Mayer G., Morbelli S., Dawson B., Pelletier A., McGill University = Université McGill [Montréal, Canada], Innsbruck Medical University [Austria] (IMU), Mayo Clinic [Rochester], Philipps University of Marburg, CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR), University of Bologna, Euromov (EuroMov), Université de Montpellier (UM), University of Genoa (UNIGE), University Medical Center Göttingen (UMG), First Faculty of Medicine Charles University [Prague], Seoul National University Hospital, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), University of Münster, Hôpital du Sacré-Coeur de Montréal, University of Oxford [Oxford], Ospedale Bellaria [Bologna, Italy], and Université du Québec à Montréal = University of Québec in Montréal (UQAM)

Subjects
0301 basic medicine, Male, Parkinson's disease, multiple system atrophy, dementia with Lewy bodies, REM sleep behaviour disorder, Kaplan-Meier Estimate, REM Sleep Behavior Disorder, Cohort Studies, 0302 clinical medicine, Risk Factors, Restless legs syndrome, Prospective Studies, Depression (differential diagnoses), Parkinsonism, Hazard ratio, Parkinson Disease, Middle Aged, Prognosis, humanities, 3. Good health, Disease Progression, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Female, Parkinson’s disease, Lewy Body Disease, medicine.medical_specialty, Polysomnography, Prodromal Symptoms, Parkinson’s disease, REM sleep behaviour disorder, dementia with Lewy bodies, multiple system atrophy, REM sleep behavior disorder, 03 medical and health sciences, Parkinsonian Disorders, Internal medicine, dementia with Lewy bodie, mental disorders, medicine, Dementia, Humans, Aged, Proportional Hazards Models, business.industry, Dementia with Lewy bodies, Scientific Commentaries, medicine.disease, 030104 developmental biology, Neurology (clinical), business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030217 neurology & neurosurgery, Forecasting
Abstract

International audience; Idiopathic REM sleep behaviour disorder (iRBD) is a powerful early sign of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. This provides an unprecedented opportunity to directly observe prodromal neurodegenerative states, and potentially intervene with neuroprotective therapy. For future neuroprotective trials, it is essential to accurately estimate phenoconversion rate and identify potential predictors of phenoconversion. This study assessed the neurodegenerative disease risk and predictors of neurodegeneration in a large multicentre cohort of iRBD. We combined prospective follow-up data from 24 centres of the International RBD Study Group. At baseline, patients with polysomnographically-confirmed iRBD without parkinsonism or dementia underwent sleep, motor, cognitive, autonomic and special sensory testing. Patients were then prospectively followed, during which risk of dementia and parkinsonsim were assessed. The risk of dementia and parkinsonism was estimated with Kaplan-Meier analysis. Predictors of phenoconversion were assessed with Cox proportional hazards analysis, adjusting for age, sex, and centre. Sample size estimates for disease-modifying trials were calculated using a time-to-event analysis. Overall, 1280 patients were recruited. The average age was 66.3 ± 8.4 and 82.5% were male. Average follow-up was 4.6 years (range = 1-19 years). The overall conversion rate from iRBD to an overt neurodegenerative syndrome was 6.3% per year, with 73.5% converting after 12-year follow-up. The rate of phenoconversion was significantly increased with abnormal quantitative motor testing [hazard ratio (HR) = 3.16], objective motor examination (HR = 3.03), olfactory deficit (HR = 2.62), mild cognitive impairment (HR = 1.91-2.37), erectile dysfunction (HR = 2.13), motor symptoms (HR = 2.11), an abnormal DAT scan (HR = 1.98), colour vision abnormalities (HR = 1.69), constipation (HR = 1.67), REM atonia loss (HR = 1.54), and age (HR = 1.54). There was no significant predictive value of sex, daytime somnolence, insomnia, restless legs syndrome, sleep apnoea, urinary dysfunction, orthostatic symptoms, depression, anxiety, or hyperechogenicity on substantia nigra ultrasound. Among predictive markers, only cognitive variables were different at baseline between those converting to primary dementia versus parkinsonism. Sample size estimates for definitive neuroprotective trials ranged from 142 to 366 patients per arm. This large multicentre study documents the high phenoconversion rate from iRBD to an overt neurodegenerative syndrome. Our findings provide estimates of the relative predictive value of prodromal markers, which can be used to stratify patients for neuroprotective trials.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results